USRE36370E - Resorbable vascular wound dressings - Google Patents
Resorbable vascular wound dressings Download PDFInfo
- Publication number
- USRE36370E USRE36370E US08/777,360 US77736096A USRE36370E US RE36370 E USRE36370 E US RE36370E US 77736096 A US77736096 A US 77736096A US RE36370 E USRE36370 E US RE36370E
- Authority
- US
- United States
- Prior art keywords
- wound dressing
- collagen
- resorbable
- vascular
- iaddend
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/11—Surgical instruments, devices or methods, e.g. tourniquets for performing anastomosis; Buttons for anastomosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
- A61F2/958—Inflatable balloons for placing stents or stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
Definitions
- This invention pertains to the field of interventional therapeutic approaches and surgical approaches to blood vessel repair and regeneration. More specifically, the present invention relates to the bioresorbable, biocompatible, non-thrombogenic, porous tubular vascular wound dressings comprised of collagen based material, which vascular wound dressings are used to repair damaged or diseased blood vessel segments so as to provide a segment of tubular vascular wound dressing to mechanically support the damaged or diseased vessel, to facilitate the regeneration of the host vessel, and to provide a means to deliver therapeutic agents at the selected sites.
- Methods of manufacturing the resorbable vascular wound dressings and methods of using the resorbable vascular wound dressings are disclosed.
- vascular graft either biological or synthetic
- a vascular graft is used to bypass the lesion to allow blood flow from the proximal to the distal end.
- an autogenous saphenous vein graft is used as a bypass graft to restore the normal blood flow in the heart.
- PTA Percutaneous transluminal angioplasty
- 4,503,569 discloses a shape memory alloy stent which is advanced to a stenosed region on a catheter.
- the stent has the form of a coil spring. After the stent is in place, the stent is heated with a hot fluid causing the shape memory alloy to expand into contact with the blood vessel.
- Stents for blood vessel repair are also disclosed in U.S. Pat. Nos. 4,553,545 and 4,732,152.
- a plastic graft for repair of vascular system is disclosed in U.S. Pat. No. 4,740,207.
- U.S. Pat. No. 4,577,631 discloses a Dacron graft that is coated with an adhesive which may be activated by ultraviolet or ultrasonic energy after placement in the aorta.
- metals have high surface energy and are not blood compatible which may therefore induce acute thrombosis when implanted as an intraluminal or intravascular stent or graft.
- metals are non-resorbable and are subject to corrosion. Even the best stainless steel cannot be guaranteed that they will not corrode under the long term implantation conditions.
- the heat expandable metal, nitinol has the additional disadvantage of incomplete expansion as a result of inadequate thermal exposure during deployment or from variabilities in stent material. Still further, migration of stents has been observed with prior art stents. Stent migration may be fatal. Stent migration may be due to under expansion, gradual change in metal properties, and the body's own defense to foreign material.
- the high temperature may have an unknown effect on the local tissue and cells.
- the melting and recrystallization within a vessel may not be a predictable event in such a life-sustaining process. Further, the long term effects of the degraded products are unknown.
- the adhesion of the polymer film with the tissue also increases the risk of fragmentation of the material which may cause potential embolization.
- Type I collagen molecule is a triple helix and has a unique protein configuration that is a coiled coil of three polypeptide chains or alpha chains. Two of the alpha chains are identical and are called alpha 1 chains and the third chain is slightly different in amino acid composition and is called alpha 2 chain.
- Each alpha chain twists in a left-handed helix with three residues per turn, and three chains are wound together in a right-handed superhelix to form a rod-like molecule about 1.4 nanometer in diameter and 300 nanometer long
- the alpha chains each contain about 1,050 amino acid residues and the molecular weight of a type I collagen molecule is about 300,000 daltons.
- every third amino acid residue is a glycine.
- Collagen is characterized by a high content of proline and hydroxyproline residues, the absence of tryptophane, a minor amount of aromatic amino acid, and a significant amount of dicarboxylic and dibasic amino residues.
- telopeptides which are globular and are not triple helical in structure and which lack glycine at every third residue. These telopeptides are the primary sites of intermolecular crosslinking in the molecule.
- type I collagen is hypo-immunogenic. Antibodies against type I collagen molecule of one species cannot be raised in the second species without the use of Freund's Complete Adjuvant. The immunogenicity is reduced when collagen is in the fiber form. Chemical crosslinking further reduces the immunogenicity to a non-detectable level. In other words, purified type I collagen fibers are highly biocompatible.
- type I collagen is biodegradable and the rate of biodegradation can be controlled by chemical means such as by crosslinking with glutaraldehyde, formaldehyde or other bifunctional crosslinking agents.
- glutaraldehyde formaldehyde or other bifunctional crosslinking agents.
- the two short triple-helices are not stable at body temperature and are denatured to random coiled peptides which are then degraded into amino acids and small peptides by proteases in the body.
- the amino acids and peptides are metabolized, presumably through the normal pathways similar to the resorption of host collagen during remodeling of the wound.
- type I collagen molecule has about 250 amino and guandino groups (positively charged groups at pH 7.4) and about 250 carboxyl groups (negatively charged groups at pH 7.4). These side chain functional groups are reactive and can be modified by chemical means to change its physico-chemical, mechanical and biological properties.
- native type I collagen fibers are thrombogenic. However, the thrombogenicity of the collagen can be significantly reduced when the collagen molecule is modified to a negatively charged protein.
- type I collagen can be prepared either as a solution or as a highly swollen fibrillar dispersion such that medicaments in the form of small molecular drugs, peptides and macromolecules can be incorporated into the collagen fibers to form a composite material that would function as a vehicle for slow systemic release or as a local delivery system of the medicaments.
- Type I collagen containing material repair of other tissues such as skin, nerve and meniscus cartilage has been attempted using type I collagen containing material.
- Yannas et. al. fabricated an endothermal implant using collagen-glycosaminoglycan composite material (U.S. Pat No. 4,060,081).
- Li used a semipermeable, resorbable type I collagen conduit for peripheral nerve repair (U.S. Pat. No. 4,963,146).
- Stone used biocompatible, resorbable type I collagen-glycosesinoglycan matrices to regenerate meniscus cartilage (U.S. Pat No. 5,007,934).
- a collagen wound healing matrix is disclosed in U.S. Pat. No. 5,024,841.
- This wound healing matrix is made from atelocollagen (pepsin solubilized skin collagen) and is not chemically crosslinked. As such, it does not possess the unique physico-chemical and mechanical properties that are critically required for the specific vascular applications of the present invention.
- vascular wound healing devices which provide structural support to the damaged or diseased vessel segment, allowing normal blood flow.
- resorbable vascular wound dressings for blood vessel repair have been discovered which eliminate or substantially reduce many of the disadvantages and problems associated with the prior attempts at vessel repair in angioplasty procedures.
- a method is provided to deliver medicaments to the selected sites inside or outside a blood vessel.
- resorbable wound dressings have been discovered which prevent or substantially reduce the risk of post-angioplasty vessel reclosure, which vascular wound dressings are tubular, compliant, self-expandable, low-profile, biocompatible, hemocompatible and bioresorbable.
- the resorbable vascular wound dressings of the present invention are generally dry, porous matrices of type I collagen containing fibers in a cylindrical form with varying inside and outside diameters.
- the fibers are randomly oriented throughout the matrix to provide radial compliance to the wound dressings.
- the matrices may also include selected medicaments for local therapeutic applications.
- Therapeutic medicaments include anti-platelet agents such as aspirin and the like, anti-coagulant agents such as coumadin and the like, antibiotics, anti-thrombus deposition agents such as polyanionic polysaccharides including heparin, chondroitin sulfates, hyaluronic acid and the like, urokinase, streptokinase, plasminogin activators and the like, wound healing agents such as transforming growth factor beta (TGF beta) and the like, glycoproteins such as laminin, fibronectin and the like, various types of collagens.
- TGF beta transforming growth factor beta
- the self-expandable vascular wound dressing of the present invention comprises a conduit having walls comprised of type I collagen matrix material having pores with an average diameter of from about 0.1 um to about 150 um and an inwardly converging tapered inner diameter.
- the invention includes a method for fabricating resorbable vascular wound dressings.
- This method comprises:
- the invention includes a method for treating a damaged or diseased blood vessel with resorbable vascular wound dressings.
- the method includes delivering the resorbable vascular wound dressing in a folded configuration to the selected site via a conventional catheter and releasing the resorbable vascular wound dressing at the selected site where the wound dressing self expands to its original configuration and adhere to the vessel wall.
- this method comprises:
- the invention includes a method for delivering resorbable vascular wound dressings at the anastomotic sites inside or outside a blood vessel during vascular surgery.
- the method for delivering a vascular wound dressing at the anastomotic site inside a blood vessel comprises:
- the method for delivering a vascular wound dressing at the anastomotic site outside a blood vessel comprises:
- the resorbable vascular wound dressings of the present invention are constructed such that the walls are substantially porous to permit nutrient diffusion for promoting endothelialization, facilitating tissue ingrowth and hastening anchorage with the host vessel. Further, the lumenal surface is non-thrombogenic and effectively prevents thrombus deposition. Still further, the resorbable wound dressings have a compliance similar to the host vessel for compliance match, reducing the potential risk of intimal hyperplasia formation. Moreover, the resorbable wound dressings have low profile walls which further reduce flow disturbances at the dressing vessel junctions. The porous walls of the resorbable vascular wound dressings provide an initial scaffold for host vessel regeneration.
- the resorbable vascular wound dressings of the present invention have the following physical characteristics and physico-chemical properties:
- FIG. 1 shows a perspective view of a resorbable vascular wound dressing made in accordance with the present invention.
- FIG. 2 shows a longitudinal cross-sectional view of the resorbable vascular wound dressing.
- FIG. 3 shows a cross-sectional view of a delivery catheter having a resorbable vascular wound dressing folded over a balloon inside a protective sheath within a blood vessel in accordance with the present invention.
- FIG. 4 shows a cross-sectional view of a deployed resorbable vascular wound dressing inside a blood vessel.
- the resorbable vascular wound dressings having specific characteristics can be fabricated from type I collagen containing material and can be introduced to the lesion site either intraluminally via a catheter or at the anastomatic sites during surgery, which wound dressings will eliminate or substantially reduce many of the disadvantages of the prior art metal and synthetic polymeric devices for vascular repair.
- Each unique characteristic and property of the resorbable vascular wound dressings and their advantages over the prior art are summarized below.
- the resorbable vascular wound dressings of the present invention have walls comprised of type 1 collagen material which is biocompatible and is further chemically modified for blood contact applications.
- walls of the resorbable vascular wound dressings of the present invention are porous having pores from about 0.1 um to about 150 um that are tortuously arranged to facilitate anchorage of the walls with the host tissue via cellular infiltration.
- the porous nature of the wound dressing also allows nutrient diffusion through the walls, thus facilitating endothelialization.
- the resorbable vascular wound dressings of the present invention have low profile walls at the distal ends as shown in member 11 of FIG. 1 and member 21 of FIG. 2.
- the walls are tapered such that the inner diameter X at the ends of the dressing are greater than the inner diameter Y at the center portions of the dressing.
- the walls of the present invention have a thickness from about 0.1 mm to about 1.5 mm in the center part of the wound dressing and from about 0.05 mm to about 0.3 mm at the ends of the wound dressing.
- the density of the resorbable vascular wound dressings of the present invention may vary from about 0.05 g/cm 3 to about 0.8 g/cm 3 , where "g/cm 3 " is a unit connoting the number of grams of wound dressing in a cubic centimeter of matrix, to accommodate various mechanical and therapeutic requirements of the wound dressings. For example, a lower density wound dressing may be more advantageous in applications where a rapid diffusion of therapeutic agents is required.
- the resorbable vascular wound dressings of the present invention have a compliance which is in the range of normal blood vessels. Compliance match between the host vessel and the implant is important. Compliance mismatch at the host vessel-implant junctions may result in turbulent blood flow and thrombus deposition, leading to smooth muscle proliferation and eventual occlusion.
- the resorbable vascular wound dressings of the present invention have a compliance from about 2.0% radial change per mm Hg ⁇ 10 -2 to about 7.0% radial change per mm Hg ⁇ 10 -2 , preferably from about 4.0% radial change per mm Hg ⁇ 10 -2 to about 6.0% radial change per mm Hg ⁇ 10 -2 .
- the resorbable vascular wound dressings of the present invention are hydrophilic which facilitates cell infiltration for rapid anchorage to the host vessel wall.
- the swelling capacity of the resorbable vascular wound dressings may vary from about 0.5 g/g wound dressing to about 15 g/g wound dressing, preferably from about 2 g/g wound dressing to about 10 g/g wound dressing.
- the rate of resorption of the resorbable vascular wound dressings of the present invention may be advantageously designed for a specific lesion site application. For example, slower in vivo resorption may be more advantageous in applications where mechanical support function of the device is critical.
- the rate of in vivo resorption can be controlled by chemical means such as by using bifunctional intermolecular crosslinking agents such as glutaraldehyde, formaldehyde or the like.
- the in vivo rate of resorption is correlated with thermal shrinkage temperature of the material.
- the thermal shrinkage temperature of the resorbable wound dressings of the present invention is from about 55° C. to about 85° C., preferably from about 60° C. to about 75° C.
- the vascular wound dressings having a shrinkage temperature of from about 55° C. to about 85° C. is resorbable in vivo in about 30 days to about 120 days.
- the resorbable vascular wound dressing 31 of the present invention can be folded over the balloon 32 at the tip of a catheter 33, to facilitate delivery via a guide wire 38 to the specific lesion site 34 within a blood vessel 35.
- the wound dressing Upon release of the device via a pull of the string 37 to remove the protective sheath 36, the wound dressing unfolds and self expands to its full original geometry 41 when in contact with blood 42 within a blood vessel.
- This self expandability of the wound dressings is of particular importance in using the wound dressings for intravascular applications.
- the relaxation recovery time which is defined as the time required for the wound dressing to transform from the folded geometry to the expanded geometry, is short for the wound dressings of the present invention.
- the relaxation recovery time of the resorbable wound dressings of the present invention is from about 1 second to about 30 seconds, preferably from about 3 seconds to about 10 seconds.
- a collagenous tissue is first subjected to purification and chemical modification procedures.
- the collagen material of the present invention may be prepared by the following methods.
- a native source of type I collagen such as skin, tendon, ligament, or bone is first cleaned of fat, fascia and other extraneous matter and washed.
- the cleaned and washed collagen containing material is then comminuted by slicing or grinding followed by extensive washing in water to remove soluble blood proteins.
- the comminuted material is then subjected to a defatting treatment using fat solubilizing agents such as low molecular weight alcohols, including ethanol and propanols, ethers, such as ethyl ether, petroleum ether, or a mixture of ether and alcohol at approximately equal volumes.
- fat solubilizing agents such as low molecular weight alcohols, including ethanol and propanols, ethers, such as ethyl ether, petroleum ether, or a mixture of ether and alcohol at approximately equal volumes.
- ether solubilizing agents such as low molecular weight alcohols, including ethanol and propanols, ethers, such as ethyl ether, petroleum ether, or a mixture of ether and alcohol at approximately equal volumes.
- the defatted and washed collagen containing material is then extracted with a neutral salt solution at a concentration of about 1M and a temperature of from about 4° C. to about 25° C. by means well known in the art.
- Neutral salt solution of high ionic strength weakens the electrostatic interactions between the collagen and non-collagenous materials.
- neutral salts include sodium chloride, potassium chloride and the like. By doing so, the neutral salt soluble non-collagenous materials are removed.
- the collagen material is then washed with deionized, distilled water.
- the salt extracted collagen containing material is further purified by a process which subjects the collagen containing material to two extreme pH extractions in the presence of a structure stabilizing salt.
- the swelling at pH from about 2 to about 3 is accomplished by means well known in the art, such as with a suitable acid.
- suitable acids include hydrochloric acid, acetic acid, lactic acid, or the like.
- the salt used may be sodium chloride, ammonium sulfate, sodium sulfate, or the like.
- the acid extraction is performed at 4° C. to minimize the bacteria growth.
- the acid weakens the ionic interactions between collagen and acidic non-collagenous proteins which are solubilized and removed.
- the collagen is extracted with a basic solution at a pH above 13 by means well known in the art.
- bases include sodium hydroxide, potassium hydroxide, calcium hydroxide, and the like.
- the alkaline condition weakens the ionic interactions between collagen and basic non-collagenous materials which are solubilized and removed.
- the alkaline treatment also reduces the isoionic point due to partial deamidation of the glutamine and asparagine residues of collagen.
- the alkaline extracted collagen material is then extensively washed with deionized, distilled water to remove the residual base and to lower the pH to from about 5 to about 7.
- the base extracted collagen is then chemically modified to partially acetylate the epsilon-amino groups of collagen to remove the positively charged epsilon-amino groups so as to further lower the isoionic point for hemocompatibility.
- Methods for acetylating the epsilon-amino groups of collagen are well known in the art such as by reacting with acetic anhydride in the presence of half saturated sodium acetate at a pH of about 8.0.
- the hemocompatibility may be enhanced by increasing the total number of negatively charged groups by subjecting the collagen to succinylation with succinic anhydride at a pH of about 8.0. By doing so, additional negative charged carboxyl groups are attached to the side chains of lysine residues.
- type I collagen material maintains fibrillar structure, contains minimal non-collagenous impurities and is well suited for additional processing for the preparation of the resorbable vascular wound dressings of the present invention.
- other types of collagen such as type II collagen, type III collagen and the like from the natural tissues may also be prepared for the intended use of the present invention.
- the purified and chemically modified collagen is first used for the preparation of a dispersion in a manner well known in the art.
- One such preparation of collagen dispersion is taught in U.S. Pat No. 3,157,524 which is incorporated herein by reference as if set out in full.
- the collagen dispersion of the present invention may be prepared by the following method.
- the purified type I collagen is first swollen with an acid solution such as hydrochloric acid, phosphoric acid, lactic acid, acetic acid and the like. Regardless of which acid is used, the pH of the acid collagen dispersion is in the range of from about 2 to about 3.
- the swollen collagen is then homogenized by any conventional means such as a homogenizer or blender so as to further dissociate the fibers.
- the homogenized collagen dispersion is then filtered to remove unswollen aggregates by means well known in the art such as by filtering through a stainless steel mesh or the like under vacuum.
- various medicaments may optionally be present in the dispersion such as aspirin, coumadin, antibiotics, polyanionic polysaccharides such as heparin, hyaluronic acid, chondroitin sulfates and the like, growth factors such as transforming growth factor beta (TGF beta) and the like, prostaglandins, plasminogen activators, urokinase, streptokinase, glycoproteins such as fibronectin, laminin and the like, type II through type XII collagens.
- TGF beta transforming growth factor beta
- the resorbable vascular wound dressings may be formed from the collagen dispersion by the following embodiments depending on the size and mechanical requirements of the wound dressings.
- the collagen fibers in the dispersion is first coacervated by adjusting the pH to its isoionic point using a base well known in the art, such as with a sodium hydroxide, ammonium hydroxide or the like.
- the coacervated fibers are fully phase separated from the water and are removed using tongs into a perforated centrifuge tube.
- the excess water associated with the hydrated fibers is removed by centrifuge at a low velocity using a commercial centrifuge.
- the partially dehydrated fibers are then fitted into a cylindrical mold which mold contains a rod in the center of the cylinder. The diameter of the rod defines the diameter of the lumen of the resorbable vascular wound dressing.
- the molded collagen fibers are then subjected to a freeze drying procedure using a commercial freeze dryer, which procedure is well know in the art.
- the collagen fibers are first frozen at a temperature below -20° C. from about 4 hours to about 8 hours, followed by drying at -10° C. for about 24 hours to about 48 hours and then at 20° C. for about 4 hours to about 8 hours at a vacuum from about 50 um Hg to about 300 um Hg.
- the thusly formed tubular porous matrix is allowed to stand overnight at room temperature to relax the fibers due to excessive vacuum treatment.
- the collagen fibers in the matrix prepared this way are randomly oriented so as to provide mechanical strength and compliance in both the longitudinal and radial directions.
- the freeze dried matrix with the rod attached is then inserted into a stirrer which rotates the matrix at a velocity of from about 20 rpm to about 700 rpm, preferably from about 40 rpm to about 400 rpm.
- a stream of water mist is sprayed onto the surface of the matrix from a distance of from about 6 inches to about 18 inches for about 5 seconds to about 30 seconds while the matrix is being rotated.
- Any commercial water sprayer such as the Compressed Air Sprayer from Consolidated Plastics Company, Inc. may be used for this purpose.
- the spray of water mist facilitates the compression process similar to the garment and laundry industries which are common in every household practice.
- the water mist treated tubular porous matrix is subjected to dual rotational compression in order to reduce the wall thickness.
- the first rotational compression step is carried out by means well known in the art such as by rotation while compressing against a smooth solid wall such as a glass surface or a plastic surface or by compressing the porous cylinder between two smooth solid surfaces during rotation.
- the outside diameter of the compressed matrix may be defined by the predetermined gap distance of the two solid plates.
- the thickness of the wall may be made according to the following formula: ##EQU1## Where O.D. equals the gap distance between the plates.
- the wall thickness is from about 0.1 mm to about 1.5 mm.
- the second compression step is carried out at the two ends of the tube to further reduce the profile of the wound dressing at the distal ends so as to form the desired taper.
- This is carried out by inserting a tapered plug (a frustum of a right circular cone) at each end of the tubular matrix.
- a tapered plug a frustum of a right circular cone
- the upper base of the frustum of the right circular cone has a diameter equal to the I.D. of the tubular matrix and the other end, lower base of the frustum of the right circular cone, has a diameter which is about 0.1 mm to about 0.6 mm smaller than the O.D. such that the inside diameter at the distal ends of the final compressed vascular wound dressing has a wall thickness of from about 0.05 mm to about 0.3 mm.
- the central rod of the mold may be cone shaped (a frustum of a right circular cone with the lower base pointing outward) at each end which dictates the size of the lumen and the wall thickness at the central portion and the ends of the resorbable vascular wound dressing upon completion of the compression step of the freeze dried matrix.
- the I.D. at the center and at the ends and the wall thickness of the resorbable vascular wound dressing may be defined by the diameter of the mandrel, the size of the upper base and the lower base of the frustum of the right circular cone and the gap distance between the two compressed plates.
- the thusly compressed tubular matrix is then subjected to a crosslinking step by methods well known in the art, such as by contacting the matrix to a bi-functional crosslinking agent including formaldehyde, glutaraldehyde, carbodiimides and the like in the vapor phase or in the liquid phase.
- Crosslinking controls the in vivo stability of the vascular wound dressings and also fixes the geometrical configuration which provides the self expandability of the wound dressings when the dressings are mechanically deformed and in contact with an aqueous solution.
- the crosslinking is performed in the vapor phase.
- the crosslinking when crosslinking is performed in the vapor phase, the crosslinking may be achieved through vapors of formaldehyde, glutaraldehyde or the like at a relative humidity of from about 75% to about 100% and at a temperature of from about 20° C. to about 30° C.
- the crosslinking may be achieved through an endothermic chemical condensation of the intermolecular side chains of collagen at a temperature between 95° C. to 110° C. and a vacuum between about 10 um Hg to about 100 um Hg for about 24 hours, known in the art as dehydrothermal crosslinking.
- the mandrel wound with a resorbable filament such as a collagen filament or a polyglyconate, a polylactate, a polyglyconatepolylactate co-polymer filament or the like.
- a resorbable filament such as a collagen filament or a polyglyconate, a polylactate, a polyglyconatepolylactate co-polymer filament or the like.
- the resorbable filament incorporates into the walls of wound dressings to provide additional rigidity to the vascular wound dressing for mechanical support requirement.
- the rigidity of the wall may be further increased by aligning the fibers in the circumferential direction. This may be accomplished by first inserting the filament wound mandrel into a mechanical stirrer and rotating the mandrel at a speed from about 10 rpm to about 60 rpm so as to slowly wrap the partially dehydrated fibers onto the coiled filament.
- the filament impregnated fibers may be further dehydrated by slowly rotating against a smooth surface such as glass before freeze drying.
- the extent of crosslinking of the vascular wound dressing can be measured by the hydrothermal shrinkage temperature of the wound dressing, i.e. the temperature at which the wound dressing in an aqueous environment begins to shrink due to unfolding of the collagen triple helix.
- the method for measuring the shrinkage temperature of a collagen material is well known in the art.
- a segment of a vascular wound dressing is first equilibrated in a 0.2M phosphate buffered solution bath at pH 7.4 at about 25° C. for about 10 minutes to about 30 minutes.
- the length of the wound dressing is determined by a cathetometer.
- the temperature of the solution is then raised by heating the solution at a rate of about 1° C. per minute.
- the length of the wound dressing is continuously recorded.
- the shrinkage temperature is defined as that temperature at which 50% reduction in the wound dressing length is reached.
- shrinkage temperature may be measured by a commercial apparatus such as a differential scanning calorimeter.
- the degree of crosslinking is such that the shrinkage temperature of the resorbable vascular wound dressing is in the range of from about 55° C. to about 85° C., preferably from about 60° C. to about 75° C.
- Such wound dressings are crosslinked to such an extent they are completely resorbed within 1 to 4 months when in the body.
- the dressing has a low profile wall at the distal and proximal ends to minimize the blood flow disturbance, a compliance match with the host vessel to minimize the hyperplasia, and a porous wall to facilitate cell infiltration whereby promoting adhesion of the wound dressing to the host vessel to prevent dressing migration.
- a wound dressing will facilitate wound healing and host vessel regeneration, permit nutrient exchange, and facilitate endothelialization.
- such a wound dressing can be mechanically deformed and it subsequently returns to its original configuration when in contact with an aqueous solution.
- the vascular wound dressings have the following physical characteristics: wall thickness from about 0.1 mm to about 1.5 mm in the center of the wound dressing and from about 0.05 mm to about 0.3 mm at the ends of the wound dressing; inside diameter from about 2 mm to about 30 mm; length from about 0.5 cm to about 15 cm; pores in the range of from about 0.1 um to about 150 um; density from about 0.05 g/cm 3 to about 0.8 g/cm 3 .
- the vascular wound dressings have the following physico-chemical properties: compliance from about 2.0% radial change per mm Hg ⁇ 10 -2 to about 7.0% radial change per mm Hg ⁇ 10 -2 , preferably from about 4% radial change per mm Hg ⁇ 10 -2 to about 6% radial change per mm Hg ⁇ 10 -2 ; swelling capacity from about 0.5 g/g to about 15 g/g, preferably from about 2.0 g/g to about 10 g/g; thermal shrinkage temperature from about 55° C. to about 85° C., preferably from about 60° C. to about 75° C.; relaxation recovery time from about 1 second to about 30 seconds, preferably from about 3 seconds to about 10 seconds.
- the resorbable vascular wound dressings made in accordance with the present invention possess unique properties not only to function as a intravascular stent to prevent or significantly reduce post-angioplasty vessel reclosure, but to repair vascular lesions resulting from annurysms and to deliver specific therapeutic agents to selective sites inside a blood vessel or at the anastomotic sites for therapeutic applications.
- the low profile wall and the compliance of the intracoronary wound dressing of the present invention significantly reduce the risk of blood flow disturbance at the dressing-host vessel junction and minimize the risk of intimal hyperplasia.
- an anti-thrombogenic and an anti-smooth muscle cell proliferation agent such as heparin and the like
- the slow release of the heparin and the like at the wound dressing surface further protects the surface from thrombus adhesion and intimal hyperplasia formation, while the dressing is slowly replaced by the regenerated host tissue.
- mechanical support may be obtained by incorporating a resorbable supporting filament into the walls, such as collagen, polyglyconate, polylactate and the like.
- the resorbable vascular wound dressings of the present invention may be advantageously delivered to the selected site of an artery via a catheter to be used after the angioplasty procedure.
- the vascular wound dressing is folded over the balloon at the tip of a percutaneous transluminal angioplasty (PTA) catheter covered with a tubular protective sheath which is attached to a string (FIG. 3).
- the sheath and the string may be made of any hemocompatible material including silicone and polyurethane.
- the vascular wound dressing Upon positioning of the wound dressing at the lesion site via a guide wire and removing of the protective sheath via the pull of the string, the vascular wound dressing self expands as it rehydrates to conform to the walls of the treated vessel.
- the balloon may be inflated to bring the vascular wound dressing into its maximal expansion within the artery.
- the balloon is then deflated and the catheter is removed upon the completion of the procedure, leaving the expanded vascular wound dressing at the selected site as shown in FIG. 4.
- the resorbable vascular wound dressing may be folded over the balloon and delivered to the lesion site during the angioplasty procedure.
- the balloon Upon the removal of the protective sheath via the pull of the string, the balloon is inflated to push the vascular wound dressing to its maximum dimension, thereby opening the vessel for normal blood flow.
- the balloon is deflated and the catheter is removed, leaving the wound dressing at the lesion site.
- the resorbable vascular wound dressings of the present invention may be advantageously used to deliver medicaments inside a blood vessel.
- the vascular wound dressing incorporated with the medicaments may be advanced to the selected site of a vessel.
- the vascular wound dressing Upon the removal of the protective sheath via the pull of the string, the vascular wound dressing self expands to adhere to the host vessel wall, leaving the desired medicaments at the specific site.
- a radiopaque material such as BaSO 4 may be incorporated into the vascular wound dressing for easy visualization.
- the resorbable vascular wound dressings of the present invention incorporated with medicaments may be advantageously delivered to the anastomotic sites either inside a vessel or outside a vessel during surgery to protect the anastomotic sites from hyperplasia formation.
- the fat and fascia of bovine flexor tendon are carefully removed and washed with water.
- the cleaned tendon is frozen and comminuted by slicing into 0.5 mm slices with a meat slicer.
- the extractant is decanted and an equal volume of isopropanol is added and the tendon slices is extracted overnight at 25° C. under constant agitation.
- the defatted tendon is extensively washed with deionized, distilled water to remove the residual isopropanol.
- the tendon is then extracted with 10 volumes of 1M NaCl for 24 hours at 4° C.
- the salt extracted tendon is washed with deionized, distilled water to remove the salt.
- the salt extracted collagen is then extracted in 10 volumes of 0.05M lactic acid solution, in the presence of 0.35M sodium sulfate at pH 2.5 for 24 hours at 4° C. under constant agitation.
- the partially swollen collagen is deswelled by slowly adding 1M NaOH to fully coacervate the collagen fibers.
- the coacervated fibers are collected with a stainless steel strainer. After washing with deionized, distilled water, the fibers are extracted with 10 volumes of 0.75M NaOH for 24 hours in the presence of 1M Na 2 SO 4 at 25° C. under constant agitation.
- the alkaline extracted collagen is collected with a strainer, neutralized with 0.1M HCl and washed with deionized, distilled water.
- the thusly purified collagen is then chemically modified with acetic anhydride in the presence of half saturated sodium acetate at room temperature.
- Acetic anhydride is slowly added through a burette to the sodium acetate solution while the pH of the solution is continuously monitored and adjusted with 1M NaOH solution to 8. The reaction is continued for 2 hours.
- the partially acetylated collagen is then washed with deionized, distilled water, freeze dried and stored dry until use.
- Example 2 An aliquot of the purified fibers prepared in Example 1 is suspended in 0.05M lactic acid solution. The amount of fibers and acid solution used is such that a 1.0% (w/v) of collagen suspension is formed. The swollen fibers are then homogenized in a stainless steel blender for 60 seconds. The dispersed collagen fiber material is filtered through a 40 um stainless steel mesh with vacuum using a filter flask.
- the collagen containing mold is then subjected to a freeze drying procedure using a Virtis commercial freeze dryer.
- the freeze dried tubular collagen sponge matrix is equilibrated at room temperature overnight.
- the mandrel with the collagen matrix is then fit into a stirrer.
- a stream of water mist is sprayed onto the collagen matrix from a distance of 12 inches while the rod is spinning at 200 rpm.
- the water mist treated collagen matrix is allow to stand for 10 minutes and the collagen matrix is then subjected to a rotational compression procedure using two plates with a gap distance of 0.46 cm.
- the compressed tubular collagen matrix is then subjected to a second compression procedure by inserting frustums of a right circular cone at the ends of the tubular matrix to reduce the wall thickness at the ends to about 0.1 mm.
- the compressed tubular collagen matrix is then crosslinked in a formaldehyde crosslinking chamber at 25° C., at 95% relative humidity and excess formaldehyde vapor for 60 minutes.
- the crosslinked collagen matrix is evacuated to remove residual formaldehyde and the individual vascular wound dressings are packaged for sterilization.
- a polyglyconate filament such as a maxon suture is first wound onto a 0.4 cm O.D. mandrel. The subsequent process is identical to the Example 2.
- a PTA balloon catheter with a vascular wound dressing folded over the balloon is inserted through the femoral artery via a percutaneous puncture site.
- the balloon with the wound dressing is guided to the selected vessel site via a guide wire.
- the protective sheath is removed by pulling the attached string.
- the balloon is inflated until a full resistance is reached at about 5 psi to about 7 psi.
- the balloon is deflated and the catheter removed, leaving the vascular wound dressing in its expanded form.
- a PTA catheter with a self expandable vascular wound dressing, made in accordance with the present invention, folded at the tip of the catheter is inserted through the femoral artery via a percutaneous puncture site.
- the wound dressing is guided to the selected vessel site via a guide wire.
- the protection sheath is removed by pulling the attached string.
- the folded wound dressing self expands to adhere to the vessel wall. The catheter is then removed.
- a percutaneous transluminal coronary angioplasty (PTCA) catheter with a resorbable vascular wound dressing folded over the balloon made in accordance with the present invention is inserted through an artery via a percutaneous puncture site.
- the balloon with the wound dressing is guided to the selected site within a coronary artery via a guide wire.
- the protection sheath is removed via a pull of the string.
- the balloon is inflated until a full resistance is reached at about 5 psi to about 7 psi, corresponding to a fully expanded vascular wound dressing.
- the balloon is then deflated and catheter removed, leaving the expanded wound dressing at the repair site.
- a PTCA catheter with a folded vascular wound dressing at the tip of the catheter, made in accordance with the present invention, is guided to the lesion site within a coronary artery.
- the protection sheath is removed by pulling the string to free the wound dressing.
- the dressing self expands to adhere to the vessel wall. The catheter is then removed.
- the vascular wound dressing of the present invention is used at anastomotic sites in conjunction with a vascular surgery procedure.
- the vascular wound dressings made in accordance with the present invention are inserted from both the proximal and distal ends to the host vessel and the vascular graft.
- the outside diameter of the vascular wound dressing is chosen to fit the inside diameter of the host vessel and the graft.
- the vascular wound dressing adheres to the vessel walls of both the host vessel and the graft at the anastomotic sites.
- Vascular wound dressings made in accordance with the present invention are inserted from the proximal and distal ends of the anastomotic sites outside the vessel walls.
- the inside diameter of the vascular wound dressing is chosen to fit the outside diameter of the host vessel and the graft.
- the vascular wound dressings are pulled to cover the anastomotic sites.
- the apparent density of the vascular wound dressing made in accordance with the Example 2 is determined by first weighing the wound dressing to obtain the weight. The volume of the wound dressing is then determined from the following formula:
- ID inside diameter of the dressing (cm)
- h length of the dressing (cm).
- the density (g/cm 3 ) is then calculated from the weight and volume of the vascular wound dressing.
- the density of the vascular wound dressings of the present invention is from about 0.05 g/cm 3 to about 0.8 g/cm 3 .
- a balloon is inserted into the lumen of a vascular wound dressing made in accordance with the Example 2.
- the outside diameter of the dressing is measured with a cathetometer.
- the balloon is inflated and the pressure inside the balloon is recorded.
- the outside diameter of the pressurized wound dressing is then measured.
- the compliance of the present invention is from about 2.0% radial change per mm Hg ⁇ 10 -2 to about 7.0% radial change per mm Hg ⁇ 10 -2 .
- the pore structure as seen by scanning electron micrographs of cross-sectional areas of the vascular wound dressing made in accordance with Example 2 are measured.
- the porous structure of the vascular wound dressings of the present invention is such that long axis of the pores are aligned circumferentially and the short axis of the pores arc perpendicular to the circumference.
- the pore size is calculated as the average between the long axis and the short axis of each pore.
- vascular wound dressings of the present invention have pores in the range of from about 0.1 um to about 150 um.
- the swelling is measured by the amount of solution uptake per unit weight of the vascular wound dressing made in accordance with the Example 2.
- the dry weight of the wound dressing is first determined.
- the wound dressing is next immersed in a buffered solution, pH 7.4 at 25° C. for one hour.
- the wet weight is then determined.
- the swelling (g/g) of the wound dressing is calculated as the difference of the wet weight and the dry weight of the wound dressing divided by the dry weight of the wound dressing.
- the swelling of the wound dressings of the present invention is from about 0.5 g/g to about 15 g/g.
- a segment of the vascular wound dressing is immersed in a buffered solution bath, pH 7.4.
- the length is recorded with a cathetometer.
- the temperature of the solution is raised at a rate of 1° C./minute.
- the temperature and the length of the samples are continuously recorded until sample shrinks and a constant length maintained.
- the shrinkage temperature is defined as the temperature where 50% change of the sample length occurs.
- the shrinkage temperature of the wound dressings of the present invention is from about about 55° C. to about 85° C.
- the wall thickness of the vascular wound dressing is measured with a micrometer.
- the wall thickness of the wound dressing is in the range of from about 0.1 mm to about 1.5 mm in the center of the dressings and in the range of from about 0.05 mm to about 0.3 mm at the distal ends of the dressings.
- the vascular wound dressing is first mechanically deformed by folding to a compact configuration similar to that folded at the tip of a catheter.
- the mechanically deformed wound dressing is then soaked in a phosphate buffered saline solution, pH 7.4 at 25° C.
- the time which takes for the deformed wound dressing to return to the original configuration is recorded as the relaxation recovery time.
- the wound dressings of the present invention have a relaxation recovery time in the range from about 1 second to about 30 seconds.
Abstract
Description
______________________________________ Physical Characteristics ______________________________________ Inside Diameter (mm) 2-30 Pore size (um) 0.1-150 Wall Thickness (mm) Distal Ends 0.15-0.30 Center 0.10-1.5 Density (g/cm.sup.3) 0.05-0.80 Length (cm) 0.5-15 ______________________________________
______________________________________ Physico-chemical Properties ______________________________________ Compliance (% radial change/mm Hg × 10.sup.2) 2.0-7.0 Swelling Capacity (g/g) 0.5-15 Thermal Stability (° C.) 55-85 Relaxation Recovery Time (second) 1-30 ______________________________________
V(cm.sup.3)=3.14×[(OD.sup.2 /4)-(ID.sup.2 /4)]×h
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/777,360 USRE36370E (en) | 1992-01-13 | 1996-12-27 | Resorbable vascular wound dressings |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82138492A | 1992-01-13 | 1992-01-13 | |
US08/046,895 US5376376A (en) | 1992-01-13 | 1993-04-15 | Resorbable vascular wound dressings |
US08/777,360 USRE36370E (en) | 1992-01-13 | 1996-12-27 | Resorbable vascular wound dressings |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US82138492A Continuation | 1992-01-13 | 1992-01-13 | |
US08/046,895 Reissue US5376376A (en) | 1992-01-13 | 1993-04-15 | Resorbable vascular wound dressings |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE36370E true USRE36370E (en) | 1999-11-02 |
Family
ID=26724412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/777,360 Expired - Lifetime USRE36370E (en) | 1992-01-13 | 1996-12-27 | Resorbable vascular wound dressings |
Country Status (1)
Country | Link |
---|---|
US (1) | USRE36370E (en) |
Cited By (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200335B1 (en) * | 1997-03-31 | 2001-03-13 | Kabushikikaisha Igaki Iryo Sekkei | Stent for vessel |
US6241719B1 (en) | 1999-05-13 | 2001-06-05 | Micro Therapeutics, Inc. | Method for forming a radioactive stent |
US20020161450A1 (en) * | 2001-04-26 | 2002-10-31 | Nobutoshi Doi | Instrument for regenerating living organism tissue or organ |
US6565601B2 (en) | 2000-11-15 | 2003-05-20 | Micro Therapeutics, Inc. | Methods for vascular reconstruction of diseased arteries |
US6569190B2 (en) | 2000-10-11 | 2003-05-27 | Micro Therapeutics, Inc. | Methods for treating aneurysms |
US20040098110A1 (en) * | 2002-11-14 | 2004-05-20 | Williams Michael S. | Photo curable endoprosthesis and method of manufacture |
US20040098090A1 (en) * | 2002-11-14 | 2004-05-20 | Williams Michael S. | Polymeric endoprosthesis and method of manufacture |
US20040122349A1 (en) * | 2002-12-20 | 2004-06-24 | Lafontaine Daniel M. | Closure device with textured surface |
US20050019488A1 (en) * | 2001-11-30 | 2005-01-27 | Cambridge Polymer Group, Inc., Boston, Ma | Layered aligned polymer structures and methods of making same |
US20050101543A1 (en) * | 2000-11-30 | 2005-05-12 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
US6932930B2 (en) | 2003-03-10 | 2005-08-23 | Synecor, Llc | Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same |
US20060052736A1 (en) * | 1998-08-27 | 2006-03-09 | Percardia, Inc. | Healing transmyocardial implant |
US7048963B2 (en) | 2001-11-30 | 2006-05-23 | Cambridge Polymers Group, Inc. | Layered aligned polymer structures and methods of making same |
US7056337B2 (en) | 2003-10-21 | 2006-06-06 | Cook Incorporated | Natural tissue stent |
US20060125142A1 (en) * | 2002-10-04 | 2006-06-15 | John Kennedy | Process of making bioabsorbable filaments |
US20060206139A1 (en) * | 2005-01-19 | 2006-09-14 | Tekulve Kurt J | Vascular occlusion device |
US20070032824A1 (en) * | 2005-08-04 | 2007-02-08 | St. Jude Medical Puerto Rico B.V. | Tissue puncture closure device with track plug |
US7285287B2 (en) | 2002-11-14 | 2007-10-23 | Synecor, Llc | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
US20070269481A1 (en) * | 2006-01-27 | 2007-11-22 | The Regents Of The University Of California | Biomimetic Scaffolds |
US20080208358A1 (en) * | 2005-03-07 | 2008-08-28 | Georgia Tech Research Corporation | Nanofilament Scaffold for Tissue Regeneration |
US20080220042A1 (en) * | 2006-01-27 | 2008-09-11 | The Regents Of The University Of California | Biomolecule-linked biomimetic scaffolds |
US20080288084A1 (en) * | 2006-08-18 | 2008-11-20 | Nobutoshi Doi | Precursor of a tissue regenerating instrument provided with a swellable rod |
US20090254104A1 (en) * | 2006-09-28 | 2009-10-08 | Children's Medical Center Corporation | Methods and collagen products for tissue repair |
US20090326577A1 (en) * | 2005-04-29 | 2009-12-31 | Johnson Chad E | Physically modified extracellular matrix materials and uses thereof |
US20100106122A1 (en) * | 2008-10-27 | 2010-04-29 | Sessions Pharmaceuticals Inc. | Fluid extracting wound dressing |
US20100211172A1 (en) * | 2007-04-02 | 2010-08-19 | Georgia Tech Research Corporation | Implantable Device For Communicating With Biological Tissue |
US20100233115A1 (en) * | 2008-10-07 | 2010-09-16 | Nanonerve, Inc. | Multilayer Fibrous Polymer Scaffolds, Methods of Production and Methods of Use |
US20100292730A1 (en) * | 2002-10-04 | 2010-11-18 | John Kennedy | Process of making bioabsorbable filaments |
US7942897B2 (en) | 2003-07-10 | 2011-05-17 | Boston Scientific Scimed, Inc. | System for closing an opening in a body cavity |
US8235939B2 (en) | 2006-02-06 | 2012-08-07 | Kci Licensing, Inc. | System and method for purging a reduced pressure apparatus during the administration of reduced pressure treatment |
US8267918B2 (en) | 2006-03-14 | 2012-09-18 | Kci Licensing, Inc. | System and method for percutaneously administering reduced pressure treatment using a flowable manifold |
US20130013083A1 (en) * | 2011-01-06 | 2013-01-10 | Humacyte | Tissue-Engineered Constructs |
US8642735B2 (en) | 1999-06-22 | 2014-02-04 | Children's Medical Center Corporation | Biologic replacement for fibrin clot |
US8709038B2 (en) | 2002-12-20 | 2014-04-29 | Boston Scientific Scimed, Inc. | Puncture hole sealing device |
US8939933B2 (en) | 2006-03-14 | 2015-01-27 | Kci Licensing, Inc. | Manifolds, systems, and methods for administering reduced pressure to a subcutaneous tissue site |
US9168231B2 (en) | 2010-12-05 | 2015-10-27 | Nanonerve, Inc. | Fibrous polymer scaffolds having diametrically patterned polymer fibers |
US9242026B2 (en) | 2008-06-27 | 2016-01-26 | Sofradim Production | Biosynthetic implant for soft tissue repair |
US9308068B2 (en) | 2007-12-03 | 2016-04-12 | Sofradim Production | Implant for parastomal hernia |
US9445883B2 (en) | 2011-12-29 | 2016-09-20 | Sofradim Production | Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit |
US9456860B2 (en) | 2006-03-14 | 2016-10-04 | Kci Licensing, Inc. | Bioresorbable foaming tissue dressing |
US9499927B2 (en) | 2012-09-25 | 2016-11-22 | Sofradim Production | Method for producing a prosthesis for reinforcing the abdominal wall |
US9526603B2 (en) | 2011-09-30 | 2016-12-27 | Covidien Lp | Reversible stiffening of light weight mesh |
US9554887B2 (en) | 2011-03-16 | 2017-01-31 | Sofradim Production | Prosthesis comprising a three-dimensional and openworked knit |
US9622843B2 (en) | 2011-07-13 | 2017-04-18 | Sofradim Production | Umbilical hernia prosthesis |
US9650603B2 (en) | 2011-01-06 | 2017-05-16 | Humacyte, Inc. | Tissue-engineered constructs |
US9750837B2 (en) | 2012-09-25 | 2017-09-05 | Sofradim Production | Haemostatic patch and method of preparation |
US9757495B2 (en) | 2013-02-01 | 2017-09-12 | Children's Medical Center Corporation | Collagen scaffolds |
US9839505B2 (en) | 2012-09-25 | 2017-12-12 | Sofradim Production | Prosthesis comprising a mesh and a strengthening means |
US9877820B2 (en) | 2014-09-29 | 2018-01-30 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
US9932695B2 (en) | 2014-12-05 | 2018-04-03 | Sofradim Production | Prosthetic porous knit |
US9931198B2 (en) | 2015-04-24 | 2018-04-03 | Sofradim Production | Prosthesis for supporting a breast structure |
US9980802B2 (en) | 2011-07-13 | 2018-05-29 | Sofradim Production | Umbilical hernia prosthesis |
US10080639B2 (en) | 2011-12-29 | 2018-09-25 | Sofradim Production | Prosthesis for inguinal hernia |
US10159555B2 (en) | 2012-09-28 | 2018-12-25 | Sofradim Production | Packaging for a hernia repair device |
US10184032B2 (en) | 2015-02-17 | 2019-01-22 | Sofradim Production | Method for preparing a chitosan-based matrix comprising a fiber reinforcement member |
US10213283B2 (en) | 2013-06-07 | 2019-02-26 | Sofradim Production | Textile-based prosthesis for laparoscopic surgery |
US10327882B2 (en) | 2014-09-29 | 2019-06-25 | Sofradim Production | Whale concept—folding mesh for TIPP procedure for inguinal hernia |
US10363690B2 (en) | 2012-08-02 | 2019-07-30 | Sofradim Production | Method for preparing a chitosan-based porous layer |
US10376226B2 (en) * | 2014-10-02 | 2019-08-13 | S. Jackson, Inc. | Method of in vivo monitoring of the condition of an internal surgical repair |
US10405960B2 (en) | 2013-06-07 | 2019-09-10 | Sofradim Production | Textile-based prothesis for laparoscopic surgery |
US10493233B1 (en) | 2018-06-05 | 2019-12-03 | Duke University | Bi-directional access to tumors |
US10646321B2 (en) | 2016-01-25 | 2020-05-12 | Sofradim Production | Prosthesis for hernia repair |
US10675137B2 (en) | 2017-05-02 | 2020-06-09 | Sofradim Production | Prosthesis for inguinal hernia repair |
US10682215B2 (en) | 2016-10-21 | 2020-06-16 | Sofradim Production | Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained |
US10743976B2 (en) | 2015-06-19 | 2020-08-18 | Sofradim Production | Synthetic prosthesis comprising a knit and a non porous film and method for forming same |
US10786239B2 (en) | 2006-01-25 | 2020-09-29 | The Children's Medical Center Corporation | Methods and procedures for ligament repair |
US10865505B2 (en) | 2009-09-04 | 2020-12-15 | Sofradim Production | Gripping fabric coated with a bioresorbable impenetrable layer |
US11273250B2 (en) | 2010-08-04 | 2022-03-15 | Georgia Tech Research Corporation | Devices, systems, and methods for excavating cancer cells |
US11471257B2 (en) | 2018-11-16 | 2022-10-18 | Sofradim Production | Implants suitable for soft tissue repair |
US11484578B2 (en) | 2012-02-01 | 2022-11-01 | Children's Medical Center Corporation | Biomaterial for articular cartilage maintenance and treatment of arthritis |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4233360A (en) * | 1975-10-22 | 1980-11-11 | Collagen Corporation | Non-antigenic collagen and articles of manufacture |
US4503569A (en) * | 1983-03-03 | 1985-03-12 | Dotter Charles T | Transluminally placed expandable graft prosthesis |
US4740207A (en) * | 1986-09-10 | 1988-04-26 | Kreamer Jeffry W | Intralumenal graft |
US4776337A (en) * | 1985-11-07 | 1988-10-11 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US5026381A (en) * | 1989-04-20 | 1991-06-25 | Colla-Tec, Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit |
US5035893A (en) * | 1988-11-29 | 1991-07-30 | Mitsubishi Kasei Corporation | Wound covering |
US5100429A (en) * | 1989-04-28 | 1992-03-31 | C. R. Bard, Inc. | Endovascular stent and delivery system |
US5116824A (en) * | 1985-05-02 | 1992-05-26 | Katakura Chikkarin Co., Ltd. | Biomaterial comprising a composite material of a chitosan derivative and collagen derivative |
-
1996
- 1996-12-27 US US08/777,360 patent/USRE36370E/en not_active Expired - Lifetime
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4233360A (en) * | 1975-10-22 | 1980-11-11 | Collagen Corporation | Non-antigenic collagen and articles of manufacture |
US4503569A (en) * | 1983-03-03 | 1985-03-12 | Dotter Charles T | Transluminally placed expandable graft prosthesis |
US5116824A (en) * | 1985-05-02 | 1992-05-26 | Katakura Chikkarin Co., Ltd. | Biomaterial comprising a composite material of a chitosan derivative and collagen derivative |
US4776337A (en) * | 1985-11-07 | 1988-10-11 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
US4776337B1 (en) * | 1985-11-07 | 2000-12-05 | Cordis Corp | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4740207A (en) * | 1986-09-10 | 1988-04-26 | Kreamer Jeffry W | Intralumenal graft |
US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US5035893A (en) * | 1988-11-29 | 1991-07-30 | Mitsubishi Kasei Corporation | Wound covering |
US5026381A (en) * | 1989-04-20 | 1991-06-25 | Colla-Tec, Incorporated | Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit |
US5100429A (en) * | 1989-04-28 | 1992-03-31 | C. R. Bard, Inc. | Endovascular stent and delivery system |
Cited By (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6200335B1 (en) * | 1997-03-31 | 2001-03-13 | Kabushikikaisha Igaki Iryo Sekkei | Stent for vessel |
US20060052736A1 (en) * | 1998-08-27 | 2006-03-09 | Percardia, Inc. | Healing transmyocardial implant |
US6241719B1 (en) | 1999-05-13 | 2001-06-05 | Micro Therapeutics, Inc. | Method for forming a radioactive stent |
US8642735B2 (en) | 1999-06-22 | 2014-02-04 | Children's Medical Center Corporation | Biologic replacement for fibrin clot |
US6569190B2 (en) | 2000-10-11 | 2003-05-27 | Micro Therapeutics, Inc. | Methods for treating aneurysms |
US20030135264A1 (en) * | 2000-10-11 | 2003-07-17 | Whalen Thomas J. | Methods for treating aneurysms |
US7083643B2 (en) | 2000-10-11 | 2006-08-01 | Micro Therapeutics, Inc. | Methods for treating aneurysms |
US6565601B2 (en) | 2000-11-15 | 2003-05-20 | Micro Therapeutics, Inc. | Methods for vascular reconstruction of diseased arteries |
US7011677B2 (en) | 2000-11-15 | 2006-03-14 | Micro Therapeutics, Inc. | Methods for vascular reconstruction of diseased arteries |
US8084491B2 (en) | 2000-11-30 | 2011-12-27 | Novodermix International Limited | Treatments for wound healing |
US20050101543A1 (en) * | 2000-11-30 | 2005-05-12 | University Of Florida | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
US20080021094A1 (en) * | 2000-11-30 | 2008-01-24 | Shapira Nathan A | Treatments for neurogenetic disorders, impulse control disorders, and wound healing |
US6953482B2 (en) * | 2001-04-26 | 2005-10-11 | Nipro Corporation | Instrument for regenerating living organism tissue or organ |
US20020161450A1 (en) * | 2001-04-26 | 2002-10-31 | Nobutoshi Doi | Instrument for regenerating living organism tissue or organ |
US20060159722A1 (en) * | 2001-11-30 | 2006-07-20 | Braithwaite Gavin J C | Layered aligned polymer structures and methods of making same |
US7048963B2 (en) | 2001-11-30 | 2006-05-23 | Cambridge Polymers Group, Inc. | Layered aligned polymer structures and methods of making same |
US20050019488A1 (en) * | 2001-11-30 | 2005-01-27 | Cambridge Polymer Group, Inc., Boston, Ma | Layered aligned polymer structures and methods of making same |
US8262963B2 (en) | 2002-10-04 | 2012-09-11 | Tyco Healthcare Group Lp | Process of making bioabsorbable filaments |
US20060125142A1 (en) * | 2002-10-04 | 2006-06-15 | John Kennedy | Process of making bioabsorbable filaments |
US20100292730A1 (en) * | 2002-10-04 | 2010-11-18 | John Kennedy | Process of making bioabsorbable filaments |
US20040098090A1 (en) * | 2002-11-14 | 2004-05-20 | Williams Michael S. | Polymeric endoprosthesis and method of manufacture |
US20040098110A1 (en) * | 2002-11-14 | 2004-05-20 | Williams Michael S. | Photo curable endoprosthesis and method of manufacture |
US7141061B2 (en) | 2002-11-14 | 2006-11-28 | Synecor, Llc | Photocurable endoprosthesis system |
US7285287B2 (en) | 2002-11-14 | 2007-10-23 | Synecor, Llc | Carbon dioxide-assisted methods of providing biocompatible intraluminal prostheses |
US20100234884A1 (en) * | 2002-12-20 | 2010-09-16 | Boston Scientific Scimed, Inc. | Closure device with textured surface |
US8398677B2 (en) | 2002-12-20 | 2013-03-19 | Boston Scientific Scimed, Inc. | Closure device with textured surface |
US20040122349A1 (en) * | 2002-12-20 | 2004-06-24 | Lafontaine Daniel M. | Closure device with textured surface |
US8709038B2 (en) | 2002-12-20 | 2014-04-29 | Boston Scientific Scimed, Inc. | Puncture hole sealing device |
US6932930B2 (en) | 2003-03-10 | 2005-08-23 | Synecor, Llc | Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same |
US8906286B2 (en) | 2003-03-10 | 2014-12-09 | Synecor, Llc | Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same |
US7919162B2 (en) | 2003-03-10 | 2011-04-05 | Synecor, Llc | Intraluminal prostheses having polymeric material with selectively modified crystallinity and methods of making same |
US20110169198A1 (en) * | 2003-03-10 | 2011-07-14 | Desimone Joseph M | Intraluminal Prostheses Having Polymeric Material with Selectively Modified Crystallinity and Methods of Making Same |
US7942897B2 (en) | 2003-07-10 | 2011-05-17 | Boston Scientific Scimed, Inc. | System for closing an opening in a body cavity |
US7056337B2 (en) | 2003-10-21 | 2006-06-06 | Cook Incorporated | Natural tissue stent |
US20060206139A1 (en) * | 2005-01-19 | 2006-09-14 | Tekulve Kurt J | Vascular occlusion device |
US8652215B2 (en) | 2005-03-07 | 2014-02-18 | Georgia Tech Research Corporation | Nanofilament scaffold for tissue regeneration |
US20080208358A1 (en) * | 2005-03-07 | 2008-08-28 | Georgia Tech Research Corporation | Nanofilament Scaffold for Tissue Regeneration |
US20090326577A1 (en) * | 2005-04-29 | 2009-12-31 | Johnson Chad E | Physically modified extracellular matrix materials and uses thereof |
US9788821B2 (en) * | 2005-04-29 | 2017-10-17 | Cook Biotech Incorporated | Physically modified extracellular matrix materials and uses thereof |
US20070032824A1 (en) * | 2005-08-04 | 2007-02-08 | St. Jude Medical Puerto Rico B.V. | Tissue puncture closure device with track plug |
US11076846B2 (en) | 2006-01-25 | 2021-08-03 | The Children's Medical Center Corporation | Methods and procedures for ligament repair |
US10786239B2 (en) | 2006-01-25 | 2020-09-29 | The Children's Medical Center Corporation | Methods and procedures for ligament repair |
US10786238B2 (en) | 2006-01-25 | 2020-09-29 | The Children's Medical Center Corporation | Methods and procedures for ligament repair |
US10786232B2 (en) | 2006-01-25 | 2020-09-29 | The Children's Medical Center Corporation | Methods and procedures for ligament repair |
US11076845B2 (en) | 2006-01-25 | 2021-08-03 | The Children's Medical Center Corporation | Methods and procedures for ligament repair |
US20080220042A1 (en) * | 2006-01-27 | 2008-09-11 | The Regents Of The University Of California | Biomolecule-linked biomimetic scaffolds |
US20070269481A1 (en) * | 2006-01-27 | 2007-11-22 | The Regents Of The University Of California | Biomimetic Scaffolds |
US8235939B2 (en) | 2006-02-06 | 2012-08-07 | Kci Licensing, Inc. | System and method for purging a reduced pressure apparatus during the administration of reduced pressure treatment |
US8617140B2 (en) | 2006-03-14 | 2013-12-31 | Kci Licensing, Inc. | System for percutaneously administering reduced pressure treatment using balloon dissection |
US9050402B2 (en) | 2006-03-14 | 2015-06-09 | Kci Licensing, Inc. | Method for percutaneously administering reduced pressure treatment using balloon dissection |
US8267918B2 (en) | 2006-03-14 | 2012-09-18 | Kci Licensing, Inc. | System and method for percutaneously administering reduced pressure treatment using a flowable manifold |
US9456860B2 (en) | 2006-03-14 | 2016-10-04 | Kci Licensing, Inc. | Bioresorbable foaming tissue dressing |
US8939933B2 (en) | 2006-03-14 | 2015-01-27 | Kci Licensing, Inc. | Manifolds, systems, and methods for administering reduced pressure to a subcutaneous tissue site |
US20080288084A1 (en) * | 2006-08-18 | 2008-11-20 | Nobutoshi Doi | Precursor of a tissue regenerating instrument provided with a swellable rod |
US8328826B2 (en) | 2006-08-18 | 2012-12-11 | Nipro Corporation | Precursor of a tissue regenerating instrument provided with a swellable rod |
US9308242B2 (en) | 2006-09-28 | 2016-04-12 | Children's Medical Center Corporation | Methods and products for tissue repair |
US20090254104A1 (en) * | 2006-09-28 | 2009-10-08 | Children's Medical Center Corporation | Methods and collagen products for tissue repair |
US9849213B2 (en) | 2006-09-28 | 2017-12-26 | Children's Medical Center Corporation | Methods and products for tissue repair |
US20100211172A1 (en) * | 2007-04-02 | 2010-08-19 | Georgia Tech Research Corporation | Implantable Device For Communicating With Biological Tissue |
US9308068B2 (en) | 2007-12-03 | 2016-04-12 | Sofradim Production | Implant for parastomal hernia |
US10368971B2 (en) | 2007-12-03 | 2019-08-06 | Sofradim Production | Implant for parastomal hernia |
US10070948B2 (en) | 2008-06-27 | 2018-09-11 | Sofradim Production | Biosynthetic implant for soft tissue repair |
US9242026B2 (en) | 2008-06-27 | 2016-01-26 | Sofradim Production | Biosynthetic implant for soft tissue repair |
US20100233115A1 (en) * | 2008-10-07 | 2010-09-16 | Nanonerve, Inc. | Multilayer Fibrous Polymer Scaffolds, Methods of Production and Methods of Use |
US8852621B2 (en) | 2008-10-07 | 2014-10-07 | Nanonerve, Inc. | Multilayer fibrous polymer scaffolds, methods of production and methods of use |
US20100106122A1 (en) * | 2008-10-27 | 2010-04-29 | Sessions Pharmaceuticals Inc. | Fluid extracting wound dressing |
US10865505B2 (en) | 2009-09-04 | 2020-12-15 | Sofradim Production | Gripping fabric coated with a bioresorbable impenetrable layer |
US11273250B2 (en) | 2010-08-04 | 2022-03-15 | Georgia Tech Research Corporation | Devices, systems, and methods for excavating cancer cells |
US9168231B2 (en) | 2010-12-05 | 2015-10-27 | Nanonerve, Inc. | Fibrous polymer scaffolds having diametrically patterned polymer fibers |
US9657265B2 (en) | 2011-01-06 | 2017-05-23 | Humacyte, Inc. | Tubular tissue-engineered constructs |
US10947498B2 (en) | 2011-01-06 | 2021-03-16 | Humacyte, Inc. | Tissue-engineered constructs |
US10619132B2 (en) | 2011-01-06 | 2020-04-14 | Humacyte, Inc. | Tissue-engineered constructs |
US20130013083A1 (en) * | 2011-01-06 | 2013-01-10 | Humacyte | Tissue-Engineered Constructs |
US10934522B2 (en) | 2011-01-06 | 2021-03-02 | Humacyte, Inc. | Tissue-engineered constructs |
US9650603B2 (en) | 2011-01-06 | 2017-05-16 | Humacyte, Inc. | Tissue-engineered constructs |
US11612472B2 (en) | 2011-03-16 | 2023-03-28 | Sofradim Production | Prosthesis comprising a three-dimensional and openworked knit |
US9554887B2 (en) | 2011-03-16 | 2017-01-31 | Sofradim Production | Prosthesis comprising a three-dimensional and openworked knit |
US10472750B2 (en) | 2011-03-16 | 2019-11-12 | Sofradim Production | Prosthesis comprising a three-dimensional and openworked knit |
US10709538B2 (en) | 2011-07-13 | 2020-07-14 | Sofradim Production | Umbilical hernia prosthesis |
US11903807B2 (en) | 2011-07-13 | 2024-02-20 | Sofradim Production | Umbilical hernia prosthesis |
US9980802B2 (en) | 2011-07-13 | 2018-05-29 | Sofradim Production | Umbilical hernia prosthesis |
US9622843B2 (en) | 2011-07-13 | 2017-04-18 | Sofradim Production | Umbilical hernia prosthesis |
US11039912B2 (en) | 2011-07-13 | 2021-06-22 | Sofradim Production | Umbilical hernia prosthesis |
US9526603B2 (en) | 2011-09-30 | 2016-12-27 | Covidien Lp | Reversible stiffening of light weight mesh |
US10080639B2 (en) | 2011-12-29 | 2018-09-25 | Sofradim Production | Prosthesis for inguinal hernia |
US11471256B2 (en) | 2011-12-29 | 2022-10-18 | Sofradim Production | Prosthesis for inguinal hernia |
US10342652B2 (en) | 2011-12-29 | 2019-07-09 | Sofradim Production | Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit |
US11266489B2 (en) | 2011-12-29 | 2022-03-08 | Sofradim Production | Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit |
US9445883B2 (en) | 2011-12-29 | 2016-09-20 | Sofradim Production | Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit |
US11925543B2 (en) | 2011-12-29 | 2024-03-12 | Sofradim Production | Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit |
US11484578B2 (en) | 2012-02-01 | 2022-11-01 | Children's Medical Center Corporation | Biomaterial for articular cartilage maintenance and treatment of arthritis |
US10363690B2 (en) | 2012-08-02 | 2019-07-30 | Sofradim Production | Method for preparing a chitosan-based porous layer |
US9499927B2 (en) | 2012-09-25 | 2016-11-22 | Sofradim Production | Method for producing a prosthesis for reinforcing the abdominal wall |
US9839505B2 (en) | 2012-09-25 | 2017-12-12 | Sofradim Production | Prosthesis comprising a mesh and a strengthening means |
US9750837B2 (en) | 2012-09-25 | 2017-09-05 | Sofradim Production | Haemostatic patch and method of preparation |
US10159555B2 (en) | 2012-09-28 | 2018-12-25 | Sofradim Production | Packaging for a hernia repair device |
US10842914B2 (en) | 2013-02-01 | 2020-11-24 | The Children's Medical Center Corporation | Collagen scaffolds |
US11826489B2 (en) | 2013-02-01 | 2023-11-28 | The Children's Medical Center Corporation | Collagen scaffolds |
US9757495B2 (en) | 2013-02-01 | 2017-09-12 | Children's Medical Center Corporation | Collagen scaffolds |
US11839696B2 (en) | 2013-02-01 | 2023-12-12 | The Children's Medical Center Corporation | Collagen scaffolds |
US10405960B2 (en) | 2013-06-07 | 2019-09-10 | Sofradim Production | Textile-based prothesis for laparoscopic surgery |
US11304790B2 (en) | 2013-06-07 | 2022-04-19 | Sofradim Production | Textile-based prothesis for laparoscopic surgery |
US11622845B2 (en) | 2013-06-07 | 2023-04-11 | Sofradim Production | Textile-based prothesis for laparoscopic surgery |
US10213283B2 (en) | 2013-06-07 | 2019-02-26 | Sofradim Production | Textile-based prosthesis for laparoscopic surgery |
US11291536B2 (en) | 2014-09-29 | 2022-04-05 | Sofradim Production | Whale concept-folding mesh for TIPP procedure for inguinal hernia |
US9877820B2 (en) | 2014-09-29 | 2018-01-30 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
US11589974B2 (en) | 2014-09-29 | 2023-02-28 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
US10327882B2 (en) | 2014-09-29 | 2019-06-25 | Sofradim Production | Whale concept—folding mesh for TIPP procedure for inguinal hernia |
US10653508B2 (en) | 2014-09-29 | 2020-05-19 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
US10376226B2 (en) * | 2014-10-02 | 2019-08-13 | S. Jackson, Inc. | Method of in vivo monitoring of the condition of an internal surgical repair |
US11266361B2 (en) * | 2014-10-02 | 2022-03-08 | S. Jackson, Inc. | Method of in vivo monitoring of the condition of an internal surgical repair |
US11359313B2 (en) | 2014-12-05 | 2022-06-14 | Sofradim Production | Prosthetic porous knit |
US11713526B2 (en) | 2014-12-05 | 2023-08-01 | Sofradim Production | Prosthetic porous knit |
US9932695B2 (en) | 2014-12-05 | 2018-04-03 | Sofradim Production | Prosthetic porous knit |
US10745835B2 (en) | 2014-12-05 | 2020-08-18 | Sofradim Production | Prosthetic porous knit |
US10184032B2 (en) | 2015-02-17 | 2019-01-22 | Sofradim Production | Method for preparing a chitosan-based matrix comprising a fiber reinforcement member |
US10815345B2 (en) | 2015-02-17 | 2020-10-27 | Sofradim Production | Method for preparing a chitosan-based matrix comprising a fiber reinforcement member |
US11439498B2 (en) | 2015-04-24 | 2022-09-13 | Sofradim Production | Prosthesis for supporting a breast structure |
US10660741B2 (en) | 2015-04-24 | 2020-05-26 | Sofradim Production | Prosthesis for supporting a breast structure |
US9931198B2 (en) | 2015-04-24 | 2018-04-03 | Sofradim Production | Prosthesis for supporting a breast structure |
US11826242B2 (en) | 2015-06-19 | 2023-11-28 | Sofradim Production | Synthetic prosthesis comprising a knit and a non porous film and method for forming same |
US10743976B2 (en) | 2015-06-19 | 2020-08-18 | Sofradim Production | Synthetic prosthesis comprising a knit and a non porous film and method for forming same |
US11389282B2 (en) | 2016-01-25 | 2022-07-19 | Sofradim Production | Prosthesis for hernia repair |
US10646321B2 (en) | 2016-01-25 | 2020-05-12 | Sofradim Production | Prosthesis for hernia repair |
US11696819B2 (en) | 2016-10-21 | 2023-07-11 | Sofradim Production | Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained |
US10682215B2 (en) | 2016-10-21 | 2020-06-16 | Sofradim Production | Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained |
US11672636B2 (en) | 2017-05-02 | 2023-06-13 | Sofradim Production | Prosthesis for inguinal hernia repair |
US10675137B2 (en) | 2017-05-02 | 2020-06-09 | Sofradim Production | Prosthesis for inguinal hernia repair |
US10493233B1 (en) | 2018-06-05 | 2019-12-03 | Duke University | Bi-directional access to tumors |
US11471257B2 (en) | 2018-11-16 | 2022-10-18 | Sofradim Production | Implants suitable for soft tissue repair |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE36370E (en) | Resorbable vascular wound dressings | |
US5376376A (en) | Resorbable vascular wound dressings | |
JP3892907B2 (en) | Inflatable and bifurcated support lumen graft | |
US5693085A (en) | Stent with collagen | |
US5871538A (en) | Luminal graft endoprotheses and manufacture thereof | |
EP1729677B1 (en) | Graft material and stent graft comprising extracellular collagen matrix and method of preparation | |
US7887576B2 (en) | Endoluminal device with extracellular matrix material and methods | |
JP3129327B2 (en) | Self-expandable stents and stent-grafts and methods of using them | |
US6165212A (en) | Expandable supportive endoluminal grafts | |
US6890351B2 (en) | Method for treating diseased or damaged organs | |
US20100094409A1 (en) | Improvements in and relating to medical devices | |
EP1746952A1 (en) | Endoluminal device with extracellular matrix material and methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
REFU | Refund |
Free format text: REFUND - PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: R1552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: SANDERLING MANAGEMENT COMPANY LLC, CALIFORNIA Free format text: SECURITY AGREEMENT;ASSIGNOR:REGEN BIOLOGICS, INC.;REEL/FRAME:024640/0249 Effective date: 20091002 |
|
AS | Assignment |
Owner name: IVY SPORTS MEDICINE, LLC, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:REGEN BIOLOGICS, INC.;RBIO, INC.;REEL/FRAME:027718/0856 Effective date: 20110630 |
|
AS | Assignment |
Owner name: REGEN BIOLOGICS, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:SANDERLING MANAGEMENT COMPANY LLC;REEL/FRAME:039809/0061 Effective date: 20110330 |